GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3D Medicines Inc (HKSE:01244) » Definitions » 3-Year Revenue Growth Rate

3D Medicines (HKSE:01244) 3-Year Revenue Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is 3D Medicines 3-Year Revenue Growth Rate?

3D Medicines's Revenue per Share for the six months ended in Dec. 2023 was HK$1.33.

During the past 12 months, 3D Medicines's average Revenue per Share Growth Rate was -78.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Competitive Comparison of 3D Medicines's 3-Year Revenue Growth Rate

For the Biotechnology subindustry, 3D Medicines's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines's 3-Year Revenue Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where 3D Medicines's 3-Year Revenue Growth Rate falls into.



3D Medicines 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


3D Medicines  (HKSE:01244) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


3D Medicines 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of 3D Medicines's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


3D Medicines (HKSE:01244) Business Description

Traded in Other Exchanges
N/A
Address
No. 3 and No. 5, Laiyang Road, Shandong, Qingdao, CHN
3D Medicines Inc is a commercial-stage biopharmaceutical company that researches, develops, and commercialization of drugs in the field of managing cancer as a chronic disease. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life.
Executives
Gong Zhaolong 2101 Beneficial owner
Zhu Pai 2101 Beneficial owner
Dragon Prosper Holdings Limited 2101 Beneficial owner
Simcere Pharmaceutical Group Limited 2101 Beneficial owner
Gong Zhaolong 2501 Other
Immunal Medixin Us Limited 2101 Beneficial owner
Kastle Limited
Shanghai Zhenlu Enterprise Management Consulting Partnership (limited Partnership) 2101 Beneficial owner
Shenzhen Efung Holding Co., Ltd. 2201 Interest of corporation controlled by you
Shenzhen Efung Investment Management Enterprise (l.p.) 2201 Interest of corporation controlled by you
Shenzhen Efung Ruishi Investment Enterprise (limited Partnership) 2201 Interest of corporation controlled by you
Zhu Jinqiao 2103 Interests held jointly with another person

3D Medicines (HKSE:01244) Headlines

No Headlines